Dr. Reddy’s Reports the Completion of Clinical Studies of Rituximab Biosimilar
Shots:
- Dr. Reddy will get ready to file in the US, EU, and other regions after the proposed rituximab biosimilar candidate DRL RI's full set of clinical studies is successfully completed
- DRL_RI references Rituxan, a cluster of differentiation 20 directed cytolytic antibody used in the treatment of adult patients with RA, non-Hodgkin's lymphoma, CLL, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis
- The biosimilar is already approved in India and over 25 other emerging markets. Dr. Reddy's is currently working with Fresenius Kabi to commercialize its proposed biosimilar of rituximab in the US & also plans to commercialize the product in the EU and other geographies
Ref: Businesswire | Image: Dr. Reddy
Related News:- Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06 study for CD20-Positive Non-Hodgkin Lymphoma
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
